| Name | Title | Contact Details |
|---|
Wisdo is an award-winning social health and clinical referral platform that addresses the adverse consequences of social isolation and loneliness on the mental and physical health of 124 million Americans. Research shows that Wisdo results in $1,900+ in annual medical cost savings, a 37% reduction in depression, a 34% increase in the number of healthy days experienced by our members, and an 80% retention rate on month 12. More than 1 million adults have joined the Wisdo community, where they realized measurable improvements in their health through community-driven social support, professionally moderated group sessions, and when appropriate clinical referrals based on predictive analytics.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
WellPath Select is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vascular Access Teaching Aids is a Oregon City, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.